<DOC>
	<DOCNO>NCT01827631</DOCNO>
	<brief_summary>This open-label , parallel group , single repeat dose pharmacokinetic ( PK ) study healthy male female subject . This study confirm PK safety profile Chinese subject . GSK1605786 currently clinical development treatment Crohn 's disease . Subjects receive one two GSK1605786 dos ( 500 mg daily 500mg twice daily ) within 30 minute meal . The study consist single repeat dose session , pre-dose serial PK sample take 72-h post-dose .</brief_summary>
	<brief_title>Single Repeat Dose Pharmacokinetic Study GSK1605786 Healthy Chinese Subjects</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test ECG Male female 18 45 year age Body weight 50 kg ( 110lbs ) men woman , body mass index ( BMI ) within range 19 24 kg/m2 A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen Current chronic history liver disease , know hepatic biliary A positive test HIV antibody screen Known coeliac disease positive serologic test antitTG antibody A positive prestudy drug/alcohol screen Lactating female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>healthy</keyword>
	<keyword>GSK1605786</keyword>
	<keyword>CCR9 receptor antagonist</keyword>
	<keyword>Chinese subject</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>